Skip to content

Psychosocial Screening for Neuroendocrine Tumor Patients

Psychosocial Screening for Neuroendocrine Tumor Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03372356
Enrollment
100
Registered
2017-12-13
Start date
2017-08-09
Completion date
2020-08-09
Last updated
2017-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine Tumors

Keywords

DT, HADS, SPBS, CD-RISC, Psychosocial Screening

Brief summary

This is a psychosocial screening application to usual care in a cohort of neuroendocrine tumor patients. The application involves monitoring using the NCCN Distress Thermometer(DT), Hospital Anxiety and Depression Scale(HADS), Self-Perceived Burden Scale(SPBS) and Connor-Davidson Resilience Scale(CD-RISC). These assessments will be completed at baseline, 3 months, 6 months, 12 months and 24 months. Patients will have the option of filling out questionnaires more frequently if desired.

Interventions

None listed

Sponsors

Peking University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. sign written informed consent form; 2. age ≥ 18 years; 3. pathologically confirmed well-differentiated neuroendocrine tumors, G1-2 (Ki67≤20%);

Exclusion criteria

1. \<18 years; 2. Neuroendocrine carcinoma; 3. History of psychiatric or psychologic illness; 4. History of previous cancers or cancer distress; 5. Patients with central nervous system(CNS) disorder; 6. Severe, uncontrolled medical condition that would affect patients' compliance;

Design outcomes

Primary

MeasureTime frameDescription
DTevery 3 month until 24 monthDistress Thermometer

Secondary

MeasureTime frameDescription
HADSevery 3 month until 24 monthHospital Anxiety and Depression Scale
SPBSevery 3 month until 24 monthSelf-Perceived Burden Scale
CD-RISCevery 3 month until 24 monthConnor-Davidson Resilience Scale

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026